Insulin therapy in people with type 2 diabetes: opportunities and challenges? - Wikidata - wikimedia - TriplyDB

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

http://www.wikidata.org/entity/Q37461707

about

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry Poor glycemic control as a reason for referral of diabetes patients to specialists in Israel.Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin.Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.Risk factors for recurrent emergency department visits for hyperglycemia in patients with diabetes mellitus.Pursuit of a perfect insulin.Clinical use of the co-formulation of insulin degludec and insulin aspart.Pancreatic islet inflammation: an emerging role for chemokines.Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508.Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.The role of beta cell heterogeneity in islet function and insulin release.Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes.

P2860

Q30249371-C40967CF-274C-4EA4-BC26-1A616CBCC75B Q35225372-EBE8AF7F-5209-4DA3-98B3-3690664DFF5A Q36134920-0E9452AE-F89A-44DF-8A00-5B4936FE7048 Q36845506-DA90CE5F-A532-4CA2-9E4C-59A813427BD3 Q37060869-FB7933E2-E603-4BCC-9937-3ED2F5443315 Q37394470-800DF38A-4BEC-4BD4-98E4-994FAF32AB49 Q37517909-C8D24F04-3CF2-43E2-B83B-946F9DFC20E2 Q37621228-31402F0E-2320-4BB3-BD83-CFCE13F6C154 Q37677863-EEE2EC7D-3E26-49B2-BA48-79E815F16F9F Q38474070-E2926677-B06D-42A7-BF2A-A2E61EF23437 Q38615808-9F81564F-B529-4F78-B700-FB059E9C0804 Q38681561-E594C3AD-FF61-4242-A314-7922ADB232BB Q38778988-D2127C5C-0393-41EB-985A-CC61462C9543 Q38887939-B118052F-0E5C-4FF8-A17C-A9142948A0E1 Q39249398-CD62A203-D6C0-4F3D-AF04-B5C155144E02 Q40269490-047FA82E-3985-428C-86A8-E80E16387CF3 Q42360595-F9F45A89-60A6-47A3-B204-7F03C9D96451 Q42371748-EC10AAEC-84A8-4605-A7C2-9222152A84EC Q47770450-7978AA79-CD11-47B7-85E5-CEA0A32A3774 Q48353746-DD50F594-C41F-4D67-8729-56C1B3B55A10 Q48576692-D3D6A9A0-0807-4917-8B13-47F5E956F1DB Q50271509-20199415-9485-4823-9B05-A63EB6BFA7C1 Q55216417-0D980752-F55B-4ED3-AFC8-824ADA24CFCF Q55317609-FAF8F42F-B316-4990-AFF6-F6F9ADFD5FB0

P2860

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

http://www.wikidata.org/entity/Q37461707

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@en

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@nl

type

label

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@en

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@nl

prefLabel

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@en

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@nl

P1433

Q37461707-4EE3033C-221C-40BF-B238-4C3955E05BA2

P1476

Q37461707-BD4682CD-E22D-4208-AEB2-2BAE99F8E075

P2093

Q37461707-2096D436-2414-478D-9909-9AB595F6C80A

Q37461707-4203F82B-1649-4D59-8DEF-EC23686CA567

Q37461707-53FE1908-7779-4430-BCBB-E7413C6371D3

Q37461707-6053BAFA-008A-41E8-80DE-D18EAB8A5157

Q37461707-6896C32B-D425-41D1-B353-9403CC32540F

Q37461707-689C7C80-2D0C-47BF-AD66-CEEE5BB5619D

Q37461707-91CEE8FC-1CF5-4767-8872-3BC39621EC2A

Q37461707-BB75BF33-12EA-4DA2-8447-C410062AD41C

Q37461707-C9C4435C-A449-47E8-A316-873EEB7FA94E

P2860

Q37461707-015E6B8B-AC6D-4859-B64B-4091F5D123E7

Q37461707-01A276F7-630E-4600-A0EE-E1DDE99A02FF

Q37461707-073E8D58-731A-485F-9EC5-A048025BD6A3

Q37461707-07892077-F1CE-4C1E-B16A-07A69257E57B

Q37461707-0E443F57-F693-4328-80B2-55494BDD8DAA

Q37461707-1CE3C25A-D93F-42CE-BBFB-8E503401E8C5

Q37461707-205CA1E4-9693-46DD-8F06-2DDB7143444C

Q37461707-220FAA69-792E-48E1-A9C9-9C8B91E99C8A

Q37461707-24EE6388-C2AA-4F49-A9E3-98D3DB7BB8E5

Q37461707-29DAA9FF-8EA6-4ECC-8B69-F6AEA29B1F13

P304

Q37461707-DDE25043-6B3B-472E-B973-305651866C5A

P31

Q37461707-BBE809B2-6C90-48BD-9E37-67746D8068B0

P356

Q37461707-8656D061-C171-4188-8E77-1BB311C22411

P407

Q37461707-05023322-E0D7-478E-BD5C-5F527E187160

P433

Q37461707-ECA5F800-4C78-4385-8587-648DCD9419FE

P478

Q37461707-675C083B-2BB2-40AD-B79E-CB06B7888286

P50

Q37461707-FEC832AD-04C4-491D-9F75-54BB3C1FCD45

P577

Q37461707-93284B5F-6EA3-4A25-A2C1-DE15DCB2CA60

P5875

Q37461707-B1DB55F5-BF46-4A7B-84B4-0346FE9EBCB1

P698

Q37461707-CD1B4B31-1C13-4EDC-8A40-C8F4571A1F8A

P921

Q37461707-B06105C0-2CD1-4643-B41B-4E3677F730E4

Q37461707-FFA9F766-1385-47CD-9740-7A120177597E

P932

Q37461707-47216B66-9BB9-4F84-ABCB-A4E9CEC72601

P356

P1433

P1476

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

@en

P2093

Clifford J Bailey

http://www.w3.org/2001/XMLSchema#string

Derek Leroith

http://www.w3.org/2001/XMLSchema#string

Guntram Schernthaner

http://www.w3.org/2001/XMLSchema#string

Itamar Raz

http://www.w3.org/2001/XMLSchema#string

Luc van Gaal

http://www.w3.org/2001/XMLSchema#string

Matthew Riddle

http://www.w3.org/2001/XMLSchema#string

Philip Home

http://www.w3.org/2001/XMLSchema#string

Reinhard G Bretzel

http://www.w3.org/2001/XMLSchema#string

Stefano Del Prato

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

10-year follow-up of intensive glucose control in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10)

P304

1499-1508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-2743

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

William T. Cefalu

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262581648

http://www.w3.org/2001/XMLSchema#string

P698

24855154

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5131884

http://www.w3.org/2001/XMLSchema#string